Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 15, 2019. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details acquisitions of GSK securities resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific share transactions.
| Instrument | Transaction Date | Price | Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (GBP) | 2019-01-11 | £15.2875 | Various (e.g., 1,535.597 for CEO) | London Stock Exchange |
| American Depositary Shares (USD) | 2019-01-11 | $39.4400 | Various (e.g., 75.536 for General Counsel) | New York Stock Exchange |
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. The only reported activity is the acquisition of shares by executives following the dividend payment on January 10, 2019.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The transactions are routine acquisitions via dividend reinvestment and do not indicate unusual items or strategic shifts.
Investor Verification Checklist
- Verify the dividend reinvestment plan terms and the specific dividend payment date of January 10, 2019.
- Confirm the market price of GSK Ordinary Shares and ADSs on January 11, 2019, to validate the transaction prices of £15.2875 and $39.4400.
- Review the total number of shares acquired by each PDMR to assess changes in executive ownership stakes.
- Check subsequent filings for any sales of these shares to determine holding periods.